Quick Summary
Financial Performance (FY 2025)
1. Total Revenue: $16.31 billion (up 5.9% year-over-year).
2. Q4 Revenue: $4.364 billion, exceeding expectations with 10.3% growth.
3. Adjusted EPS: $11.92 for the full year; $3.42 for the fourth quarter.
4. R&D Backlog: Reached a record $32.7 billion, with $8.3 billion expected to convert to revenue in 2026.
2026 Financial Guidance
1. Revenue Projection: Between $17.15 billion and $17.35 billion.
2. Adjusted EPS Projection: $12.55 to $12.85.
4. Profitability: Anticipating roughly $80 million in interest expense headwinds, offset by operational efficiencies.
IQVIA Holdings Inc. (NYSE: IQV), a global leader in clinical research, healthcare intelligence, and data analytics, reported strong financial results for the fourth quarter and full year of 2025, signaling a robust recovery in demand across its core segments. Despite a volatile macroeconomic landscape, the company exceeded Wall Street’s revenue and earnings estimates, while laying out an ambitious technology-first roadmap for 2026.
Financial Highlights: Ending 2025 on a High Note
IQVIA’s fourth-quarter revenue reached $4.364 billion, a 10.3% increase on a reported basis compared to the same period in 2024. For the full year, the company generated $16.31 billion in revenue, representing 5.9% year-over-year growth.
The company’s profitability also saw a significant boost. Adjusted diluted earnings per share (EPS) for the fourth quarter came in at $3.42, surpassing analyst consensus. This growth was fueled by strong performance across all three primary divisions:
- Technology & Analytics Solutions (TAS): Revenue grew 9.8% to $1.82 billion.
- Research & Development Solutions (R&DS): Revenue rose 9.9% to $2.33 billion.
- Contract Sales & Medical Solutions (CSMS): Revenue surged 18.6% to $210 million.
IQVIA closed 2025 with strong performance across all segments,
We delivered near double-digit revenue growth in the fourth quarter, driven by continued investments in our clinical and commercial offerings and a stabilization in customer decision-making.
Ari Bousbib
Read More: IQVIA Posts Strong Q3 2025 Results, Lifts Free Cash Flow
The AI Revolution: Med-R1 and Strategic Partnerships
The 2025 earnings report was accompanied by a clear message: IQVIA is positioning itself as the “operating system” for AI in life sciences. In recent months, the company has secured high-profile partnerships to bolster its “Healthcare-grade AI” capabilities:
- AWS Collaboration: IQVIA named Amazon Web Services (AWS) as its preferred “agentic cloud provider” to power a next-generation AI platform.
- NVIDIA Partnership: The company is collaborating with NVIDIA to launch specialized AI agents designed to accelerate clinical trial workflows.
- Proprietary Models: IQVIA recently introduced “Med-R1 8B,” a medical reasoning Large Language Model (LLM) built to assist healthcare organizations with complex decision-making and patient outcome analysis.
Bousbib addressed investor concerns regarding AI disruption, asserting that IQVIA’s proprietary data assets are “more valuable than ever” and cannot be replicated by general-purpose AI models.
Operational Realignment: A New Look for 2026
To better align with industry trends, IQVIA announced a major segment reorganization effective January 1, 2026. The TAS and CSMS segments have been merged into a single division called Commercial Solutions. Simultaneously, certain Real-World Late Phase offerings have been moved into the R&DS segment to streamline clinical research operations.
This realignment comes as the company continues to win major contracts, including a recent “strategic long-term global commercial data foundation transformation” deal with Boehringer Ingelheim announced in late January.
2026 Guidance and Market Outlook
Looking ahead, IQVIA issued full-year 2026 guidance that reflects confidence in its market position, though it remains cautious about rising interest expenses.
- Revenue: Expected to be between $17.15 billion and $17.35 billion.
- Adjusted EPS: Forecasted at $12.55 to $12.85.
The company anticipates a roughly $80 million headwind from higher interest expenses in 2026 but expects to offset this through operational efficiencies and the conversion of its massive $32.7 billion R&D backlog.
Last Modified:
